Immunologische Konsequenzen, Rheuma, Infektionen

  • Thomas Harrer

Auszug

Die Blockade des Chemokinrezeptors 5 (CCR5) durch kleinmolekulare CCR5-Inhibitoren wie Maraviroc hat neue Möglichkeiten für die Therapie von CCR5-tropen HI-Viren eröffnet. Da Chemokinrezeptoren eine wichtige Rolle in der Immunantwort spielen, stellt sich natürlich die Frage, welche Folgen eine pharmakologische Blockade von CCR5 für die Abwehr von Infektionen und die Entstehung von entzündlichen Erkrankungen haben kann. Ein gutes Verständnis der Rolle des Chemokin-Chemokinrezeptor-Systems ist daher entscheidend für die Abschätzung der Konsequenzen einer pharmakologischen Intervention.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adarichev VA, Vermes C, Hanyecz A, et al. Antigen-induced differential gene expression in lymphocytes and gene expression profile in synovium prior to the onset of arthritis. Autoimmunity 2006; 39:663–673PubMedCrossRefGoogle Scholar
  2. Aguilar F, Nunez-Roldan A, Torres B, Wichmann I, Sanchez-Roman J, Gonzalez-Escribano MF. Chemokine receptor CCR2/CCR5 polymorphism in Spanish patients with systemic lupus erythematosus. J Rheumatol 2003; 30:1770–1774PubMedGoogle Scholar
  3. Ahlenstiel G, Berg T, Woitas RP, et al. Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C. J Hepatol 2003; 39:245–252PubMedCrossRefGoogle Scholar
  4. Aliberti J, Reis e Sousa C, Schito M, et al. CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat Immunol 2000; 1:83–87PubMedCrossRefGoogle Scholar
  5. Andres PG, Beck PL, Mizoguchi E, et al. Mice with a selective deletion of the CC chemokine receptors 5 or 2 Are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J Immunol 2000; 164:6303–6312PubMedGoogle Scholar
  6. Ank N, Petersen K, Malmgaard L, Mogensen SC, Paludan SR. Age-dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2. J. Viro. 2005; 79:9831–9841CrossRefGoogle Scholar
  7. Apolinario A, Majano PL, Alvarez-Perez E, et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol 2002; 97:2861–2870PubMedCrossRefGoogle Scholar
  8. Balistreri CR, Grimaldi MP, Vasto S, et al. Association between the polymorphism of CCR5 and Alzheimer’s disease: results of a study performed on male and female patients from Northern Italy. Ann N Y Acad Sci 2006; 1089:454–461PubMedCrossRefGoogle Scholar
  9. Baragiotta A, Floreani A, Agarwal K, et al. Chemokine receptor 5 and primary biliary cirrhosis: a two-centre genetic association study. Liver Int 2004; 24:646–650PubMedCrossRefGoogle Scholar
  10. Barcellos LF, Schito AM, Rimmler JB, et al. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics 2000; 51:281–288PubMedCrossRefGoogle Scholar
  11. Barr EL, Ouburg S, Igietseme JU, et al. Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion. J Microbiol Immunol Infect 2005; 38:244–254PubMedGoogle Scholar
  12. Bennetts BH, Teutsch SM, Buhler MM, Heard RN, Stewart GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 1997; 58:52–59PubMedCrossRefGoogle Scholar
  13. Berthoux FC, Berthoux P, Mariat C, Thibaudin L, Afiani A, Linossier MT. CC-chemokine receptor five gene polymorphism in primary IgA nephropathy: the 32 bp deletion allele is associated with late progression to end-stage renal failure with dialysis. Kidney Int 2006; 69:565–572PubMedCrossRefGoogle Scholar
  14. Borczuk AC, Papanikolaou N, Toonkel RL, et al. Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES. Oncogene 2007; 23:23Google Scholar
  15. Burns JC, Shimizu C, Gonzalez E, et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J Infect Dis 2005; 192:344–349PubMedCrossRefGoogle Scholar
  16. Cooke SP, Forrest G, Venables PJ, Hajeer A. The delta32 deletion of CCR5 receptor in rheumatoid arthritis. Arthritis Rheum 1998; 41:1135–1136PubMedCrossRefGoogle Scholar
  17. Dawson TC, Beck MA, Kuziel WA, Henderson F, Maeda N. Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol 2000; 156:1951–1959PubMedGoogle Scholar
  18. de Roda Husman A-M, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127:882–890PubMedGoogle Scholar
  19. Dean M, Jacobson LP, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res 1999; 59:3561–3564PubMedGoogle Scholar
  20. Desmetz C, Lin YL, Mettling C, et al. Cell surface CCR5 density determines the intensity of T cell migration towards rheumatoid arthritis synoviocytes. Clin Immunol. 2007; 123:148–154PubMedCrossRefGoogle Scholar
  21. Diamond MS, Klein RS. A genetic basis for human susceptibility to West Nile virus. Trends Microbiol 2006; 14:287–289PubMedCrossRefGoogle Scholar
  22. Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15:726–731PubMedCrossRefGoogle Scholar
  23. Eltayeb S, Berg AL, Lassmann H, et al. Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE. J Neuroinflammation 2007; 4:14PubMedCrossRefGoogle Scholar
  24. Eri R, Jonsson JR, Pandeya N, et al. CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. Genes Immun 2004; 5:444–450PubMedCrossRefGoogle Scholar
  25. Eugen-Olsen J, Iversen AK, Garred P, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. Aids 1997; 11:305–310PubMedCrossRefGoogle Scholar
  26. Favorova OO, Andreewski TV, Boiko AN, et al. The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology 2002; 59:1652–1655PubMedGoogle Scholar
  27. Gade-Andavolu R, Comings DE, MacMurray J, et al. Association of CCR5 delta32 deletion with early death in multiple sclerosis. Genet Med 2004; 6:126–131PubMedCrossRefGoogle Scholar
  28. Galimberti D, Fenoglio C, Lovati C, et al. CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer’s disease. J Neurol Sci 2004; 225:79–83PubMedCrossRefGoogle Scholar
  29. Galvani AP, Novembre J. The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. Microbes Infect 2005; 7:302–309PubMedCrossRefGoogle Scholar
  30. Galvani AP, Slatkin M. Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele. Proc Natl Acad Sci USA 2003; 100:15276–15279PubMedCrossRefGoogle Scholar
  31. Gambelunghe G, Ghaderi M, Gharizadeh B, et al. Lack of association of human chemokine receptor gene polymorphisms CCR2-64I and CCR5-Delta32 with autoimmune Addison’s disease. Eur J Immunogenet 2004; 31:73–76PubMedCrossRefGoogle Scholar
  32. Garred P, Madsen HO, Petersen J, et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998; 25:1462–1465PubMedGoogle Scholar
  33. Ghilardi G, Biondi ML, Battaglioli L, Zambon A, Guagnellini E, Scorza R. Genetic risk factor characterizes abdominal aortic aneurysm from arterial occlusive disease in human beings: CCR5 Delta 32 deletion. J Vasc Surg 2004; 40:995–1000PubMedCrossRefGoogle Scholar
  34. Glas J, Torok HP, Simperl C, et al. The Delta 32 mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon-alpha and ribavirin. Clin Immunol 2003; 108:46–50PubMedCrossRefGoogle Scholar
  35. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005; 202:1087–1098PubMedCrossRefGoogle Scholar
  36. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006; 203:35–40PubMedCrossRefGoogle Scholar
  37. Gomez-Reino JJ, Pablos JL, Carreira PE, et al. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum 1999; 42:989–992PubMedCrossRefGoogle Scholar
  38. Gonzalez P, Alvarez R, Batalla A, et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun 2001; 2:191–195PubMedCrossRefGoogle Scholar
  39. Goulding C, McManus R, Murphy A, et al. The CCR5-{Delta}32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005; 54:1157–1161PubMedCrossRefGoogle Scholar
  40. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196:304–312PubMedCrossRefGoogle Scholar
  41. Haase CG, Schmidt S, Faustmann PM. Frequencies of the G-protein beta3 subunit C825T polymorphism and the delta 32 mutation of the chemokine receptor-5 in patients with multiple sclerosis. Neurosci Lett 2002; 330:293–295PubMedCrossRefGoogle Scholar
  42. Hall IP, Wheatley A, Christie G, McDougall C, Hubbard R, Helms PJ. Association of CCR5 delta32 with reduced risk of asthma. Lancet 1999; 354:1264–1265PubMedCrossRefGoogle Scholar
  43. Hellier S, Frodsham AJ, Hennig BJ, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003; 38:1468–1476PubMedGoogle Scholar
  44. Henckaerts L, Fevery J, Van Steenbergen W, et al. CC-type chemokine receptor 5-Delta32 mutation protects against primary sclerosing cholangitis. Inflamm Bowel Dis 2006; 12:272–277PubMedCrossRefGoogle Scholar
  45. Herfarth H, Pollok-Kopp B, Goke M, Press A, Oppermann M. Polymorphism of CC chemokine receptors CCR2 and CCR5 in Crohn’s disease. Immunol Lett 2001; 77:113–117PubMedCrossRefGoogle Scholar
  46. Hisada M, Lal RB, Masciotra S, et al. Chemokine receptor gene polymorphisms and risk of human T lymphotropic virus type I infection in Jamaica. J Infect Dis 2002; 185:1351–1354PubMedCrossRefGoogle Scholar
  47. Houle M, Thivierge M, Le Gouill C, Stankova J, Rola-Pleszczynski M. IL-10 up-regulates CCR5 gene expression in human monocytes. Inflammation 1999; 23:241–251PubMedGoogle Scholar
  48. Huerta C, Alvarez V, Mata IF, et al. Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer’s and Parkinson’s disease. Neurosci Lett 2004; 370:151–154PubMedCrossRefGoogle Scholar
  49. Huffnagle GB, McNeil LK, McDonald RA, et al. Cutting Edge: role of C-C chemokine receptor 5 in organ-specific and innate immunity to cryptococcus neoformans. J Immunol 1999; 163:4642–4646PubMedGoogle Scholar
  50. John S, Smith S, Morrison JF, et al. Genetic variation in CCR5 does not predict clinical outcome in inflammatory arthritis. Arthritis Rheum 2003; 48:3615–3616PubMedCrossRefGoogle Scholar
  51. Kaimen-Maciel DR, Vissoci Reiche EM, Brum Souza DG, et al. CCR5-Delta32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis. Int J Mol Med 2007; 20:337–344PubMedGoogle Scholar
  52. Kantarci OH, Morales Y, Ziemer PA, et al. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol 2005; 169:137–143PubMedCrossRefGoogle Scholar
  53. Kasten S, Goldwich A, Schmitt M, et al. Positive influence of the Delta32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1 infected patients. Eur J Med Res 2000; 5:323–328PubMedGoogle Scholar
  54. Khan IA, Thomas SY, Moretto MM, et al. CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection. PLoS Pathog 2006; 2:e49PubMedCrossRefGoogle Scholar
  55. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006; 296:815–826PubMedCrossRefGoogle Scholar
  56. Lim JK, Glass WG, McDermott DH, Murphy PM. CCR5: no longer a »good for nothing« gene — chemokine control of West Nile virus infection. Trends Immunol 2006; 27:308–312PubMedCrossRefGoogle Scholar
  57. Lindner E, Nordang GB, Melum E, et al. Lack of association between the chemokine receptor 5 polymorphism CCR5-delta32 in rheumatoid arthritis and juvenile idiopathic arthritis. BMC Med Genet 2007; 8:33PubMedCrossRefGoogle Scholar
  58. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367–377PubMedCrossRefGoogle Scholar
  59. Lu Y, Nerurkar VR, Dashwood WM, et al. Genotype and allele frequency of a 32-base pair deletion mutation in the CCR5 gene in various ethnic groups: absence of mutation among Asians and Pacific Islanders. Int J Infect Dis 1999; 3:186–191PubMedCrossRefGoogle Scholar
  60. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001; 2:102–107PubMedCrossRefGoogle Scholar
  61. Ma B, Kang M-J, Lee CG, et al. Role of CCR5 in IFN-{gamma}-induced and cigarette smoke-induced emphysema. J Clin Invest 2005; 115:3460–3472PubMedCrossRefGoogle Scholar
  62. Mack M, Cihak J, Simonis C, et al. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J Immunol 2001; 166:4697–4704PubMedGoogle Scholar
  63. McGinnis R, Child F, Clayton S, et al. Further support for the association of CCR5 allelic variants with asthma susceptibility. Eur J Immunogenet 2002; 29:525–528PubMedCrossRefGoogle Scholar
  64. Melum E, Karlsen TH, Broome U, et al. The 32-base pair deletion of the chemokine receptor 5 gene (CCR5-Delta32) is not associated with primary sclerosing cholangitis in 363 Scandinavian patients. Tissue Antigens 2006; 68:78–81PubMedCrossRefGoogle Scholar
  65. Mettimano M, Specchia ML, La Torre G, et al. Blood pressure regulation by CCR genes. Clin Exp Hypertens 2006; 28:611–618PubMedCrossRefGoogle Scholar
  66. Meyer L, Magierowska M, Hubert JB, et al. CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. The SEROCO-HEMOCO-SEROGEST Study Groups. J Infect Dis 1999; 180:920–924PubMedCrossRefGoogle Scholar
  67. Meyer L, Magierowska M, Hubert JB, et al. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group. Aids 1997; 11:F73–78PubMedCrossRefGoogle Scholar
  68. Mitchell TJ, Walley AJ, Pease JE, et al. Delta 32 deletion of CCR5 gene and association with asthma or atopy. Lancet 2000; 356:1491–1492PubMedCrossRefGoogle Scholar
  69. Mojtahedi Z, Ahmadi SB, Razmkhah M, Azad TK, Rajaee A, Ghaderi A. Association of chemokine receptor 5 (CCR5) delta32 mutation with Behcet’s disease is dependent on gender in Iranian patients. Clin Exp Rheumatol 2006; 24:S91–4PubMedGoogle Scholar
  70. Mokubo A, Tanaka Y, Nakajima K, et al. Chemotactic cytokine receptor 5 (CCR5) gene promoter polymorphism (59029A/G) is associated with diabetic nephropathy in Japanese patients with type 2 diabetes: a 10-year longitudinal study. Diabetes Res Clin Pract 2006; 73:89–94PubMedCrossRefGoogle Scholar
  71. Nahon P, Sutton A, Rufat P, et al. Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study. Eur J Gastroenterol Hepatol 2007; 19:425–431PubMedCrossRefGoogle Scholar
  72. Nansen A, Christensen JP, Andreasen SO, Bartholdy C, Christensen JE, Thomsen AR. The role of CC chemokine receptor 5 in antiviral immunity. Blood 2002; 99:1237–1245PubMedCrossRefGoogle Scholar
  73. Nattermann J, Nischalke HD, Feldmann G, Ahlenstiel G, Sauerbruch T, Spengler U. Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5. J Viral Hepat 2004; 11:519–526PubMedCrossRefGoogle Scholar
  74. Nguyen GT, Carrington M, Beeler JA, et al. Phenotypic expressions of CCR5-delta32/delta32 homozygosity. J Acquir Immune Defic Syndr 1999; 22:75–82PubMedGoogle Scholar
  75. Otaegui D, Ruiz-Martinez J, Olaskoaga J, Emparanza JI, de Munain AL. Influence of CCR5-Delta32 genotype in Spanish population with multiple sclerosis. Neurogenetics. 2007; 8:201–205PubMedCrossRefGoogle Scholar
  76. Pai JK, Kraft P, Cannuscio CC, et al. Polymorphisms in the CC-chemokine receptor-2 (CCR2) and-5 (CCR5) genes and risk of coronary heart disease among US women. Atherosclerosis 2006; 186:132–139PubMedCrossRefGoogle Scholar
  77. Panzer U, Schneider A, Steinmetz OM, et al. The chemokine receptor 5 Delta32 mutation is associated with increased renal survival in patients with IgA nephropathy. Kidney Int 2005; 67:75–81PubMedCrossRefGoogle Scholar
  78. Petrek M, Drabek J, Kolek V, et al. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2000; 162:1000–1003PubMedGoogle Scholar
  79. Pokorny V, McQueen F, Yeoman S, et al. Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann Rheum Dis 2005; 64:487–490PubMedCrossRefGoogle Scholar
  80. Prahalad S, Bohnsack JF, Jorde LB, et al. Association of two functional polymorphisms in the CCR5 gene with juvenile rheumatoid arthritis. Genes Immun 2006; 7:468–475PubMedCrossRefGoogle Scholar
  81. Prasad P, Tiwari AK, Kumar KM, et al. Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med Genet 2007; 8:20PubMedCrossRefGoogle Scholar
  82. Promrat K, McDermott DH, Gonzalez CM, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003; 124:352–360PubMedCrossRefGoogle Scholar
  83. Pulkkinen K, Luomala M, Kuusisto H, et al. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. Acta Neurol Scand 2004; 109:342–347PubMedCrossRefGoogle Scholar
  84. Rabkin CS, Yang Q-e, Goedert JJ, Nguyen G, Mitsuya H, Sei S. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin’s lymphoma in human immunodeficiency virus-1-infected individuals. Blood 1999; 93:1838–1842PubMedGoogle Scholar
  85. Rasmussen HB, Timm S, Wang AG, et al. Association between the CCR5 32-bp deletion allele and late onset of schizophrenia. Am J Psychiatry 2006; 163:507–511PubMedCrossRefGoogle Scholar
  86. Ristic S, Lovrecic L, Starcevic-Cizmarevic N, et al. No association of CCR5delta32 gene mutation with multiple sclerosis in Croatian and Slovenian patients. Mult Scler 2006; 12:360–362PubMedCrossRefGoogle Scholar
  87. Salvarani C, Boiardi L, Timms JM, et al. Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica. Clin Exp Rheumatol 2000; 18:591–595PubMedGoogle Scholar
  88. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722–725PubMedCrossRefGoogle Scholar
  89. Sandford AJ, Zhu S, Bai TR, Fitzgerald JM, Pare PD. The role of the C-C chemokine receptor-5 Delta32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted. J Allergy Clin Immunol 2001; 108:69–73PubMedCrossRefGoogle Scholar
  90. Sato N, Kuziel WA, Melby PC, et al. Defects in the generation of IFN-γ are overcome to control infection with leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1α-, or CCR2-deficient mice. J Immunol 1999; 163:5519–5525PubMedGoogle Scholar
  91. Schreiber K, Otura AB, Ryder LP, et al. Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). Mult Scler 2002; 8:295–258PubMedCrossRefGoogle Scholar
  92. Scott Algood HM, Flynn JL. CCR5-deficient mice control mycobacterium tuberculosis infection despite increased pulmonary lymphocytic infiltration. J Immunol 2004; 173:3287–3296Google Scholar
  93. Sellebjerg F, Kristiansen TB, Wittenhagen P, et al. Chemokine receptor CCR5 in interferon-treated multiple sclerosis. Acta Neurol Scand 2007; 115:413–418PubMedCrossRefGoogle Scholar
  94. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 2000; 102:98–106PubMedCrossRefGoogle Scholar
  95. Shieh B, Liau YE, Hsieh PS, Yan YP, Wang ST, Li C. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int Immunol 2000; 12:1311–1318PubMedCrossRefGoogle Scholar
  96. Silversides JA, Heggarty SV, McDonnell GV, Hawkins SA, Graham CA. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler 2004; 10:149–152PubMedCrossRefGoogle Scholar
  97. Soo HM, Garzino-Demo A, Hong W, et al. Expression of a full-length hepatitis C virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES. Virology 2002; 303:253–277PubMedCrossRefGoogle Scholar
  98. Spagnolo P, Renzoni EA, Wells AU, et al. C-C chemokine receptor 5 gene variants in relation to lung disease in sarcoidosis. Am J Respir Crit Care Med 2005; 172:721–728PubMedCrossRefGoogle Scholar
  99. Szalai C, Csaszar A, Czinner A, et al. Chemokine receptor CCR2 and CCR5 polymorphisms in children with insulin-dependent diabetes mellitus. Pediatr Res 1999; 46:82–84PubMedCrossRefGoogle Scholar
  100. Szalai C, Duba J, Prohaszka Z, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients. Atherosclerosis 2001; 158:233–239PubMedCrossRefGoogle Scholar
  101. Szczucinski A, Losy J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 2007; 115:137–146PubMedCrossRefGoogle Scholar
  102. Thapa M, Kuziel WA, Carr DJ. Susceptibility of CCR5-deficient mice to genital herpes simplex virus type 2 is linked to NK cell mobilization. J Virol 2007; 81:3704–3713PubMedCrossRefGoogle Scholar
  103. Thio CL, Astemborski J, Bashirova A, et al. Genetic protection against hepatitis B virus conferred by CCR5Δ32: evidence that CCR5 contributes to viral persistence. J Virol 2007; 81:441–445PubMedCrossRefGoogle Scholar
  104. Thoelen I, Verbeeck J, Wollants E, et al. Frequency of the CCR5-Delta32 mutant allele is not increased in Belgian hepatitis C virus-infected patients. Viral Immunol 2005; 18:232–235PubMedCrossRefGoogle Scholar
  105. Tran EH, Kuziel WA, Owens T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor. Eur J Immunol 2000; 30:1410–1415PubMedCrossRefGoogle Scholar
  106. Ugurel S, Schrama D, Keller G, et al. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother 2007; 2:2Google Scholar
  107. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006; 66:124–134PubMedCrossRefGoogle Scholar
  108. van Deventer HW, O’Connor W, Jr., Brickey WJ, Aris RM, Ting JP, Serody JS. C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res 2005; 65:3374–3379PubMedGoogle Scholar
  109. van Rij RP, Portegies P, Hallaby T, et al. Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex. J Infect Dis 1999; 180:854–857PubMedCrossRefGoogle Scholar
  110. van Veen T, Nielsen J, Berkhof J, et al. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J Neuroimmunol 2007; 18:18Google Scholar
  111. Wasmuth HE, Werth A, Mueller T, et al. CC chemokine receptor 5 delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia. J Mol Med 2004; 82:64–69PubMedCrossRefGoogle Scholar
  112. Wheeler J, McHale M, Jackson V, Penny M. Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc. Antivir Ther 2007; 12:233–245PubMedGoogle Scholar
  113. Woitas RP, Ahlenstiel G, Iwan A, et al. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology 2002; 122:1721–1728PubMedCrossRefGoogle Scholar
  114. Yang B, Houlberg K, Millward A, Demaine A. Polymorphisms of chemokine and chemokine receptor genes in Type 1 diabetes mellitus and its complications. Cytokine 2004; 26:114–121PubMedCrossRefGoogle Scholar
  115. Yang YF, Mukai T, Gao P, et al. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur J Immunol 2002; 32:2124–132PubMedCrossRefGoogle Scholar
  116. Zapico I, Coto E, Rodriguez A, Alvarez C, Torre JC, Alvarez V. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun 2000; 1:288–289PubMedCrossRefGoogle Scholar
  117. Zhang M, Ardlie K, Wacholder S, Welch R, Chanock S, O’Brien TR. Genetic variations in CC chemokine receptors and hypertension. Am J Hypertens 2006; 19:67–72PubMedCrossRefGoogle Scholar
  118. Zhao X, Gharizadeh B, Hjelmstrom P, et al. Genotypes of CCR2 and CCR5 chemokine receptors in human myasthenia gravis. Int J Mol Med. 2003; 12:749–753PubMedGoogle Scholar
  119. Zheng B, Wiklund F, Gharizadeh B, et al. Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res 2006; 26:3669–3674PubMedGoogle Scholar
  120. Zhong MX, Kuziel WA, Pamer EG, Serbina NV. Chemokine receptor 5 is dispensable for innate and adaptive immune responses to listeria monocytogenes infection. Infect Immun 2004; 72:1057–1064PubMedCrossRefGoogle Scholar
  121. Zhou Y, Kurihara T, Ryseck R-P, et al. Impaired macrophage function and enhanced t cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 1998; 160:4018–4025PubMedGoogle Scholar
  122. Zou W, Foussat A, Houhou S, et al. Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV-infected patients treated with interleukin-2. ANRS 048 IL-2 Study Group. Aids 1999; 13:455–463PubMedCrossRefGoogle Scholar
  123. Zuniga JA, Villarreal-Garza C, Flores E, et al. Biological relevance of the polymorphism in the CCR5 gene in refractory and non-refractory rheumatoid arthritis in Mexicans. Clin Exp Rheumatol 2003; 21:35–354Google Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2008

Authors and Affiliations

  • Thomas Harrer
    • 1
  1. 1.Medizinische Klinik IIIUniversitätsklinikum ErlangenErlangen

Personalised recommendations